Multidistrict Litigation (MDL) Created For Elmiron Eye Damage & Vision Loss Lawsuits

More than a hundred filed lawsuits allege Johnson & Johnson and Janssen Pharmaceutical’s drug Elmiron (pentosyn polysulfate) is the cause of the plaintiffs’ vision loss.

No Longer Accepting Cases
Our law firm is no longer accepting Elmiron cases. If you feel that you may have a case, we urge you to contact another firm adequately suited to handle your case.

Johnson//Becker is a nationwide plaintiff’s law firm with experience representing injured men and women in lawsuits against pharmaceutical and medical device companies. Johnson//Becker represents a number of individuals who allege they have suffered permanent vision loss after use of the drug Elmiron.

This past week, the Judicial Panel on Multidistrict Litigation issued an order created an MDL for the federal cases and centralizing the cases in the Distrist of New Jersey before the Honorable Brian Martinotti. The case is MDL 2973 – In re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation.

Johnson & Johnson is a New Jersey Corporation. Janssen Pharmaceuticals, part of the Johnson & Johnson umbrella of companies, is a Pennsylvania corporation. These companies have marketed Elmiron since the 2000s. The Plaintiffs allege that the company has never provided any warning of maculopathy or retinopathy associated with use of the drug or warned patients to have regular eye exams to monitor vision while using the drug until the company updated the label in June, 2020.

Timothy J. Becker and Stacy K Hauer of Johnson//Becker are counsel of record. Mr. Becker and Ms. Hauer have a combined experience of more than 40 years of litigating mass tort cases involving pharmaceuticals and medical devices.

Meet The Elmiron Litigation Team

Learn more about the Elmiron Litigation Team at Johnson//Becker and Meet the Attorney and Co-Chair of our Consumer Products and Mass Tort Department by downloading the Elmiron Litigation Guide.